Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vicuron's Dalbavancin User Fee Date Extended To Sept. 21

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA extends user fee deadline for the lipoglycopeptide antibiotic by three months to review additional chemistry, manufacturing & controls data. Vicuron plans to amend the NDA for its antifungal anidulafungin in the second quarter.

You may also be interested in...



Pfizer’s Dalbavancin “Approvable”

FDA issued an "approvable" letter for Pfizer's lipoglycopeptide antibiotic dalbavancin Sept. 21, the agency said

Pfizer’s Dalbavancin “Approvable”

FDA issued an "approvable" letter for Pfizer's lipoglycopeptide antibiotic dalbavancin Sept. 21, the agency said

Vicuron Submits NDA For Additional Anidulafungin Indication

The invasive candidiasis/candidemia indication was spun off from a pending NDA for esophageal candidiasis.

Related Content

Topics

UsernamePublicRestriction

Register

PS062191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel